美国 · SEC FORM 4
Aldeyra Therapeutics, Inc.
ALDX · Nasdaq · CIK 0001341235 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $417.5K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ 角色得分低 · 买入者中职位最高的是：President and CEO（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 45.0
- 45.0
- 44.9
- 44.8
- 44.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -37.3%
- 3M
- -52.5%
- 6M
- -48.5%
- 12M
- -83.7%
波动率与流动性
- 波动率
- 112.5%
- Beta
- —
- 平均每日成交额
- USD 1.1M
估值
- 市值
- USD 55.3M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -76.5%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-04 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 3,470,527
- 上期报告
- 3,604,007
- 日均成交量
- 1,149,748
- 回补天数
- 3.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Brady Todd C | 买入 (P) | Common Stock | 250,000 | USD 1.67 | USD 417,500 | SEC 申报 ↗ |
| 2026-03-19 | DOUGLAS RICHARD | 买入 (P) | Common Stock | 70,000 | USD 1.40 | USD 98,000 | SEC 申报 ↗ |
| 2026-03-18 | Alfieri Michael | 买入 (P) | Common Stock | 5,000 | USD 1.42 | USD 7,100 | SEC 申报 ↗ |
| 2025-08-13 | Alfieri Michael | 买入 (P) | Common Stock | 2,500 | USD 5.30 | USD 13,250 | SEC 申报 ↗ |
| 2024-04-05 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 37,712 | USD 4.74 | USD 178,755 | SEC 申报 ↗ |
| 2024-04-04 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 140,281 | USD 4.67 | USD 655,112 | SEC 申报 ↗ |
| 2024-04-03 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 309,847 | USD 4.09 | USD 1,267,274 | SEC 申报 ↗ |
| 2024-04-02 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 186,051 | USD 3.44 | USD 640,015 | SEC 申报 ↗ |
| 2024-04-01 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 8,374 | USD 3.25 | USD 27,216 | SEC 申报 ↗ |
| 2023-04-12 | Miller-Rich Nancy | 买入 (P) | Common Stock | 509 | USD 10.13 | USD 5,156 | SEC 申报 ↗ |
| 2022-08-10 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 15,000 | USD 7.85 | USD 117,750 | SEC 申报 ↗ |
| 2022-08-09 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 100,000 | USD 7.50 | USD 750,000 | SEC 申报 ↗ |
| 2022-08-08 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 97,000 | USD 7.24 | USD 702,280 | SEC 申报 ↗ |
| 2022-08-05 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 141,000 | USD 6.95 | USD 979,950 | SEC 申报 ↗ |
| 2022-08-04 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 95,100 | USD 6.17 | USD 586,767 | SEC 申报 ↗ |
Form 4 申报证据
3 transaction lines in the latest 365-day window; 63 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Brady Todd C | 买入 (P) | Common Stock | 250,000 | USD 1.67 | USD 417,500 | SEC 申报 ↗ |
| 2026-03-19 | DOUGLAS RICHARD | 买入 (P) | Common Stock | 70,000 | USD 1.40 | USD 98,000 | SEC 申报 ↗ |
| 2026-03-18 | Alfieri Michael | 买入 (P) | Common Stock | 5,000 | USD 1.42 | USD 7,100 | SEC 申报 ↗ |
展开近期 Form 4 证据 (3 grouped rows)
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ALDX |
| CIK | 0001341235 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 63 transaction lines from 2020-03-02 to 2026-06-03 31 P purchase lines · 13 S sale lines · 19 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.